LT3417883T - Tikslingai nukreipti alfa-dalelės emituojantys kompleksai, apimantys torio radionuklidą ir hidroksipiridinono turintį ligandą - Google Patents
Tikslingai nukreipti alfa-dalelės emituojantys kompleksai, apimantys torio radionuklidą ir hidroksipiridinono turintį ligandąInfo
- Publication number
- LT3417883T LT3417883T LTEP18163914.7T LT18163914T LT3417883T LT 3417883 T LT3417883 T LT 3417883T LT 18163914 T LT18163914 T LT 18163914T LT 3417883 T LT3417883 T LT 3417883T
- Authority
- LT
- Lithuania
- Prior art keywords
- hydroxypyridinone
- containing ligand
- particle emitting
- emitting complexes
- targeted alpha
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
- A61K51/0478—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group complexes from non-cyclic ligands, e.g. EDTA, MAG3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
- A61K51/1051—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from breast, e.g. the antibody being herceptin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
- A61K51/1072—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from the reproductive system, e.g. ovaria, uterus, testes or prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1002508.8A GB201002508D0 (en) | 2010-02-12 | 2010-02-12 | Product |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| LT3417883T true LT3417883T (lt) | 2020-07-10 |
Family
ID=42110714
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| LTEP18163914.7T LT3417883T (lt) | 2010-02-12 | 2011-02-14 | Tikslingai nukreipti alfa-dalelės emituojantys kompleksai, apimantys torio radionuklidą ir hidroksipiridinono turintį ligandą |
| LTEP11702857.1T LT2533817T (lt) | 2010-02-12 | 2011-02-14 | Tikslingai nukreipti alfa daleles emituojantys kompleksai, apimantys torio radionuklidą ir hidroksipiridinono turintį ligandą |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| LTEP11702857.1T LT2533817T (lt) | 2010-02-12 | 2011-02-14 | Tikslingai nukreipti alfa daleles emituojantys kompleksai, apimantys torio radionuklidą ir hidroksipiridinono turintį ligandą |
Country Status (26)
| Country | Link |
|---|---|
| US (2) | US9724436B2 (lt) |
| EP (2) | EP2533817B1 (lt) |
| JP (2) | JP5878483B2 (lt) |
| KR (1) | KR101931382B1 (lt) |
| CN (1) | CN103608043B (lt) |
| AU (1) | AU2011214281B2 (lt) |
| BR (1) | BR112012020304B1 (lt) |
| CA (1) | CA2789433C (lt) |
| CY (1) | CY1120362T1 (lt) |
| DK (2) | DK3417883T3 (lt) |
| EA (1) | EA026305B1 (lt) |
| ES (2) | ES2794853T3 (lt) |
| GB (1) | GB201002508D0 (lt) |
| HR (2) | HRP20180996T1 (lt) |
| HU (2) | HUE038013T2 (lt) |
| IL (2) | IL221416A (lt) |
| LT (2) | LT3417883T (lt) |
| MX (1) | MX343405B (lt) |
| NZ (1) | NZ601867A (lt) |
| PL (2) | PL2533817T3 (lt) |
| PT (2) | PT2533817T (lt) |
| RS (2) | RS60314B1 (lt) |
| SG (1) | SG183279A1 (lt) |
| SI (2) | SI3417883T1 (lt) |
| TR (1) | TR201809149T4 (lt) |
| WO (1) | WO2011098611A2 (lt) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2659251C (en) | 2006-07-10 | 2016-06-14 | The Regents Of The University Of California | Luminescent 1-hydroxy-2-pyridinone chelates of lanthanides |
| WO2011025790A1 (en) | 2009-08-24 | 2011-03-03 | Lumiphore, Inc. | Macrocyclic hopo chelators |
| GB201002508D0 (en) * | 2010-02-12 | 2010-03-31 | Algeta As | Product |
| GB201208309D0 (en) * | 2012-05-11 | 2012-06-27 | Algeta As | Complexes |
| ES2738474T3 (es) | 2013-01-14 | 2020-01-23 | Molecular Insight Pharm Inc | Radiofármacos a base de triazina y agentes radioimagenológicos |
| US11453652B2 (en) | 2013-03-15 | 2022-09-27 | Lumiphore, Inc. | Di-macrocycles |
| GB201310028D0 (en) | 2013-06-05 | 2013-07-17 | Algeta Asa | Pharmaceutical preparation |
| MA41176A (fr) * | 2014-12-17 | 2017-10-24 | Bayer As | Complexes radio-pharmaceutiques |
| US10434186B2 (en) * | 2014-12-22 | 2019-10-08 | Lumiphore, Inc. | Functionalized linear ligands and complexes thereof |
| GB201504064D0 (en) | 2015-03-10 | 2015-04-22 | Accretion Biotechnology Ltd | Method and kits for preparing radionuclide complexes |
| GB201600154D0 (en) * | 2016-01-05 | 2016-02-17 | Bayer As | Isotope preparation method |
| GB201600153D0 (en) * | 2016-01-05 | 2016-02-17 | Bayer As | Isotope preparation method |
| GB201600161D0 (en) * | 2016-01-05 | 2016-02-17 | Bayer As | Isotope purification method |
| WO2017162555A1 (en) * | 2016-03-24 | 2017-09-28 | Bayer Pharma Aktiengesellschaft | Radio-pharmaceutical complexes |
| MX2018015340A (es) * | 2016-06-10 | 2019-03-28 | Bayer Pharma AG | Complejos radio-farmaceuticos. |
| CA3054248A1 (en) | 2017-02-24 | 2018-08-30 | Bayer As | Combination therapy comprising a radiopharmaceutical and a dna-repair inhibitor |
| WO2019115684A1 (en) | 2017-12-13 | 2019-06-20 | Sciencons AS | Complex comprising a psma-targeting compound linked to a lead or thorium radionuclide |
| CA3110754A1 (en) | 2018-08-28 | 2020-03-05 | Bayer As | Combination of pi3k-inhibitors and targeted thorium conjugates |
| US20220040338A1 (en) * | 2018-10-16 | 2022-02-10 | Nant Holdings Ip, Llc | Alpha Emitter Compositions And Methods |
| CA3130747A1 (en) | 2019-02-21 | 2020-08-27 | Bayer Aktiengesellschaft | Combination of pd-1/pd-l1 inhibitors and targeted thorium conjugates |
| EP3927339A1 (en) | 2019-02-22 | 2021-12-29 | Bayer Aktiengesellschaft | Combination of ar antagonists and targeted thorium conjugates |
| US20230072421A1 (en) | 2019-07-25 | 2023-03-09 | Bayer As | Targeted radiopharmaceuticals for the diagnosis and treatment of prostate cancer |
| JP2024503908A (ja) | 2021-01-22 | 2024-01-29 | バイエル アクチェンゲゼルシャフト | Ｌｒｒｃ１５抗体およびそのコンジュゲート |
| US11541134B1 (en) | 2021-08-02 | 2023-01-03 | Rayzebio, Inc. | Stabilized compositions of radionuclides and uses thereof |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE68925904T2 (de) | 1988-05-25 | 1996-10-31 | Us Commerce | Makrocyclische chelate und verwendungsverfahren |
| DE69007430T2 (de) | 1989-06-19 | 1994-07-07 | Akzo Nobel Nv | Radioimmuntherapie unter alphapartikelausstrahlung. |
| WO1993020852A2 (en) | 1992-04-13 | 1993-10-28 | The Dow Chemical Company | Macrocyclic chelating agents, chelates and conjugates thereof |
| US5624901A (en) * | 1994-04-15 | 1997-04-29 | The Regents Of The University Of California | 3-hydroxy-2(1H)-pyridinone chelating agents |
| WO1997000245A1 (en) * | 1995-06-14 | 1997-01-03 | The Regents Of The University Of California | 3-hydroxy-2(1h)-pyridinone chelating agents |
| JP2001503253A (ja) | 1996-10-17 | 2001-03-13 | イムノメディクス，インコーポレイテッド | 非抗原性即素複合体およびインターナライジング受容体システムの融合タンパク |
| WO1998027209A1 (en) | 1996-12-18 | 1998-06-25 | Emory University | Polycationic oligomers |
| NO310544B1 (no) | 1999-01-04 | 2001-07-23 | Algeta As | Opparbeidelse og anvendelse av radium-223 til fremstilling av preparat samt kit til behandling av kalsifisert vev for palliasjon, benkreft-terapi og/eller overflatebehandling av ben |
| MY133346A (en) | 1999-03-01 | 2007-11-30 | Biogen Inc | Kit for radiolabeling ligands with yttrium-90 |
| US7144991B2 (en) | 1999-06-07 | 2006-12-05 | Aletheon Pharmaceuticals, Inc. | Streptavidin expressed gene fusions and methods of use thereof |
| NO314537B1 (no) | 1999-12-06 | 2003-04-07 | Anticancer Therapeutic Inv Sa | Reseptorbindende konjugater |
| NO312708B1 (no) | 2000-02-21 | 2002-06-24 | Anticancer Therapeutic Inv Sa | Radioaktive liposomer til terapi |
| HUP0203743A2 (en) | 2000-02-25 | 2003-02-28 | R Keith Frank | Actinium-225 complexes and conjugates for radioimmunotherapy |
| NO313180B1 (no) | 2000-07-04 | 2002-08-26 | Anticancer Therapeutic Inv Sa | Bensökende alfapartikkel emitterende radiofarmasöytika |
| US7893223B2 (en) * | 2001-07-17 | 2011-02-22 | Bracco Imaging S.P.A. | Multidentate AZA ligands able to complex metal ions and the use thereof in diagnostics and therapy |
| GB0213261D0 (en) | 2002-06-10 | 2002-07-17 | Anticancer Therapeutic Inv Sa | Method |
| US20030228256A1 (en) | 2002-06-11 | 2003-12-11 | Inverardi Luca A. | Methods of achieving transplantation tolerance through radioablation of hemolymphopoietic cell populations |
| US20030086868A1 (en) | 2002-08-12 | 2003-05-08 | Dangshe Ma | Actinium-225 complexes and conjugates for radioimmunotherapy |
| ITMI20022411A1 (it) | 2002-11-14 | 2004-05-15 | Bracco Imaging Spa | Agenti per la diagnosi e la terapia di tumori che espongono sulla superficie delle cellule proteine alterate. |
| US20060228297A1 (en) | 2003-04-15 | 2006-10-12 | Roy Larsen | Thorium-227 for use in radiotherapy of soft tissue disease |
| GB0308731D0 (en) | 2003-04-15 | 2003-05-21 | Anticancer Therapeutic Inv Sa | Method of radiotherapy |
| CA2522148C (en) * | 2003-04-15 | 2010-07-13 | Algeta As | Thorium-227 for use in radiotherapy of soft tissue disease |
| EP1735013B1 (en) | 2004-02-20 | 2012-02-08 | Algeta ASA | Alpha- and beta-emitting hydroxyapatite particles |
| EP1763372B1 (en) * | 2004-06-25 | 2016-11-30 | The European Union, represented by the European Commission | Radionuclides for medical use |
| GB0423565D0 (en) | 2004-10-22 | 2004-11-24 | Algeta As | Formulation |
| CA2659251C (en) * | 2006-07-10 | 2016-06-14 | The Regents Of The University Of California | Luminescent 1-hydroxy-2-pyridinone chelates of lanthanides |
| ES2655082T3 (es) | 2006-08-15 | 2018-02-16 | The Regents Of The University Of California | Complejos luminiscentes de lantánidos macrocíclicos |
| US8158804B2 (en) * | 2007-01-11 | 2012-04-17 | Ge Healthcare As | Chelating agents |
| EP2516407A4 (en) * | 2009-12-24 | 2013-06-12 | Lumiphore Inc | RADIOPHARMACEUTICAL COMPLEXES |
| GB201002508D0 (en) * | 2010-02-12 | 2010-03-31 | Algeta As | Product |
| GB201007354D0 (en) | 2010-04-30 | 2010-06-16 | Algeta Asa | Method |
| GB201007353D0 (en) | 2010-04-30 | 2010-06-16 | Algeta Asa | Method |
| GB201105298D0 (en) | 2011-03-29 | 2011-05-11 | Algeta Asa | Pharmaceutical preparation |
| GB201208309D0 (en) | 2012-05-11 | 2012-06-27 | Algeta As | Complexes |
-
2010
- 2010-02-12 GB GBGB1002508.8A patent/GB201002508D0/en not_active Ceased
-
2011
- 2011-02-14 HU HUE11702857A patent/HUE038013T2/hu unknown
- 2011-02-14 PT PT117028571T patent/PT2533817T/pt unknown
- 2011-02-14 NZ NZ601867A patent/NZ601867A/en unknown
- 2011-02-14 EP EP11702857.1A patent/EP2533817B1/en active Active
- 2011-02-14 SG SG2012059622A patent/SG183279A1/en unknown
- 2011-02-14 MX MX2012009260A patent/MX343405B/es active IP Right Grant
- 2011-02-14 TR TR2018/09149T patent/TR201809149T4/tr unknown
- 2011-02-14 EA EA201290712A patent/EA026305B1/ru unknown
- 2011-02-14 HU HUE18163914A patent/HUE049465T2/hu unknown
- 2011-02-14 PL PL11702857T patent/PL2533817T3/pl unknown
- 2011-02-14 AU AU2011214281A patent/AU2011214281B2/en active Active
- 2011-02-14 ES ES18163914T patent/ES2794853T3/es active Active
- 2011-02-14 CA CA2789433A patent/CA2789433C/en active Active
- 2011-02-14 LT LTEP18163914.7T patent/LT3417883T/lt unknown
- 2011-02-14 RS RS20200596A patent/RS60314B1/sr unknown
- 2011-02-14 PL PL18163914T patent/PL3417883T3/pl unknown
- 2011-02-14 US US13/578,578 patent/US9724436B2/en active Active
- 2011-02-14 CN CN201180018732.8A patent/CN103608043B/zh active Active
- 2011-02-14 DK DK18163914.7T patent/DK3417883T3/da active
- 2011-02-14 DK DK11702857.1T patent/DK2533817T3/en active
- 2011-02-14 SI SI201131886T patent/SI3417883T1/sl unknown
- 2011-02-14 JP JP2012552424A patent/JP5878483B2/ja active Active
- 2011-02-14 KR KR1020127023753A patent/KR101931382B1/ko active IP Right Grant
- 2011-02-14 ES ES11702857.1T patent/ES2674875T3/es active Active
- 2011-02-14 WO PCT/EP2011/052158 patent/WO2011098611A2/en active Application Filing
- 2011-02-14 BR BR112012020304A patent/BR112012020304B1/pt active IP Right Grant
- 2011-02-14 SI SI201131515T patent/SI2533817T1/en unknown
- 2011-02-14 RS RS20180744A patent/RS57360B1/sr unknown
- 2011-02-14 EP EP18163914.7A patent/EP3417883B1/en active Active
- 2011-02-14 PT PT181639147T patent/PT3417883T/pt unknown
- 2011-02-14 LT LTEP11702857.1T patent/LT2533817T/lt unknown
-
2012
- 2012-08-12 IL IL221416A patent/IL221416A/en active IP Right Grant
-
2015
- 2015-11-25 JP JP2015229526A patent/JP6125599B2/ja active Active
- 2015-12-23 IL IL243303A patent/IL243303A/en active IP Right Grant
-
2017
- 2017-06-21 US US15/629,409 patent/US10682430B2/en active Active
-
2018
- 2018-06-27 CY CY20181100669T patent/CY1120362T1/el unknown
- 2018-06-28 HR HRP20180996TT patent/HRP20180996T1/hr unknown
-
2020
- 2020-05-21 HR HRP20200826TT patent/HRP20200826T1/hr unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL2533817T3 (pl) | Ukierunkowane kompleksy emitujące cząstki alfa zawierające radionuklid toru i hydroksypirydynon zawierający ligand | |
| ZA201406969B (en) | Combination therapy with an anti-hyaluronan agent and a tumor-targreted taxane | |
| HK1206982A1 (en) | Radio-pharmaceutical complexes | |
| EP2820630A4 (en) | VIRTUAL GUARDING WITH LOCATION AGENT | |
| EP2751270A4 (en) | OLIGOMER CONJUGATE COMPLEXES AND ITS USE | |
| SG11201500546RA (en) | Vascular access device and guiding portion | |
| EP2841103A4 (en) | LIGAND-DRUG CONJUGATES DR5 | |
| IL251974A0 (en) | Antifibrosis compounds and their uses | |
| EP2537530A4 (en) | RADIOTHERAPY AGENT | |
| IL233402B (en) | User application for geographic-spatial location information of a released criminal | |
| EP2875014A4 (en) | ANTI-MUCUS MEDICAMENTS AND USES THEREOF | |
| HRP20150560T1 (en) | Radiolabelled phenylimidazole-based ligands | |
| IL223707A0 (en) | N-hydroxyformamide derivative and medicament containing same | |
| EP2831737A4 (en) | SOFTWARE DEVELOPMENT ACTIVITY | |
| HK1213221A1 (zh) | 銀粉 | |
| GB201003483D0 (en) | Gold complexes | |
| GB201312905D0 (en) | A Protection and Carrier System | |
| GB201202622D0 (en) | Brachytherapy system & in vivo dose detector therefor | |
| EP2557076A4 (en) | ANTI-LEISHMANIA COMPOUND AND ANTI-LEISHMANIA ACTIVE SUBSTANCE | |
| HK1204282A1 (en) | Drug composition, and soft capsule containing same | |
| EP2857028A4 (en) | AGENT CONTAINING ASCORBIC ACID DERIVATIVE AND USE THEREOF | |
| TWI559972B (en) | Microparticle and addition agent | |
| GB201204745D0 (en) | Identifying proximity and location | |
| TWM403055U (en) | Storage type mouse pad |